1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
- A Novel Topical PPAR 3 Agonist Induces PPAR 3 Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models
- Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
- 2017
- Long-term effectiveness of vedolizumab in inflammatory bowel disease : a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
- Prebiotics and synbiotics in ulcerative colitis
- Immunopathology of Inflammatory Bowel Disease
- 2016
- Dairy products, dietary calcium, and risk of inflammatory bowel disease : Results from a European prospective cohort investigation
- Telocytes, communicators in healthy stroma and relation to inflammation and fibrosis
- 2014
- Exploring the microbiota of the gastrointestinal tract
- 2012
- Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study